Marvel Biosciences Corp.
MBCOF
$0.0629
-$0.0021-3.23%
OTC PK
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.67% | -32.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 128.04% | -32.59% | |||
| Operating Income | -128.04% | 32.59% | |||
| Income Before Tax | -67.66% | 52.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -67.66% | 52.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.66% | 52.83% | |||
| EBIT | -128.04% | 32.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -65.22% | 57.01% | |||
| Normalized Basic EPS | -71.43% | 58.21% | |||
| EPS Diluted | -65.22% | 57.01% | |||
| Normalized Diluted EPS | -71.43% | 58.21% | |||
| Average Basic Shares Outstanding | 0.01% | 10.59% | |||
| Average Diluted Shares Outstanding | 0.01% | 10.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||